Dare Bioscience (DARE)
2.00
0.00 (0.00%)
Upcoming Events
Latest Headlines
Dare Bioscience launches Flora Sync LF5 vaginal probiotic capsules
June 4, 2026 8:02 AM - StreetInsider
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules
June 4, 2026 8:00 AM - Globe NewsWire
Form DEFA14A Dare Bioscience, Inc.
June 1, 2026 5:15 PM - SEC Filing
Form DEFA14A Dare Bioscience, Inc.
June 1, 2026 9:00 AM - SEC Filing
Daré Bioscience receives $1M NIH funding for HPV treatment
May 26, 2026 8:01 AM - StreetInsider
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer
May 26, 2026 8:00 AM - Globe NewsWire
Form 8-K Dare Bioscience, Inc. For: May 14
May 18, 2026 4:29 PM - SEC Filing
Daré Bioscience begins phase 2 trial of HPV infection treatment
May 18, 2026 8:01 AM - StreetInsider
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
May 18, 2026 8:01 AM - Globe NewsWire
Form 253G2 Dare Bioscience, Inc.
May 15, 2026 6:14 AM - SEC Filing
Dare Bioscience (DARE) Misses Q1 EPS by 20c
May 14, 2026 4:08 PM - StreetInsider
Form 10-Q Dare Bioscience, Inc. For: Mar 31
May 14, 2026 4:05 PM - SEC Filing
Form 8-K Dare Bioscience, Inc. For: May 14
May 14, 2026 4:02 PM - SEC Filing
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update
May 14, 2026 4:01 PM - Globe NewsWire
Daré Bioscience reports interim Phase 3 results for hormone-free contraceptive
May 12, 2026 8:01 AM - StreetInsider
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive
May 12, 2026 8:00 AM - Globe NewsWire
Form 8-K Dare Bioscience, Inc. For: May 01
May 7, 2026 4:13 PM - SEC Filing
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026
May 7, 2026 8:00 AM - Globe NewsWire
Form ARS Dare Bioscience, Inc. For: Dec 31
April 28, 2026 4:43 PM - SEC Filing
Form DEFA14A Dare Bioscience, Inc.
April 28, 2026 4:34 PM - SEC Filing
Form DEF 14A Dare Bioscience, Inc. For: Jun 11
April 28, 2026 4:02 PM - SEC Filing
Form 8-K Dare Bioscience, Inc. For: Apr 22
April 22, 2026 9:03 AM - SEC Filing
Form 8-K Dare Bioscience, Inc. For: Apr 17
April 20, 2026 4:08 PM - SEC Filing
Form 8-K Dare Bioscience, Inc. For: Apr 16
April 17, 2026 4:11 PM - SEC Filing
Form PRE 14A Dare Bioscience, Inc. For: Jun 11
April 17, 2026 4:05 PM - SEC Filing
Form 8-K Dare Bioscience, Inc. For: Apr 10
April 13, 2026 4:59 PM - SEC Filing
Form QUALIF Dare Bioscience, Inc.
April 2, 2026 6:07 AM - SEC Filing
Form 1-A POS Dare Bioscience, Inc.
March 30, 2026 6:06 AM - SEC Filing
Form 253G2 Dare Bioscience, Inc.
March 30, 2026 6:06 AM - SEC Filing
Form 10-K Dare Bioscience, Inc. For: Dec 31
March 26, 2026 4:03 PM - SEC Filing
Form 8-K Dare Bioscience, Inc. For: Mar 26
March 26, 2026 4:01 PM - SEC Filing
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update
March 26, 2026 4:01 PM - Globe NewsWire
On National Viagra Day, Women Finally Claim Their Turn:
March 23, 2026 8:00 AM - Globe NewsWire
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026
March 20, 2026 8:00 AM - Globe NewsWire
Form 8-K Dare Bioscience, Inc. For: Mar 16
March 17, 2026 4:38 PM - SEC Filing
Dare Bioscience receives NIH funding extension for preterm birth treatment
March 16, 2026 8:02 AM - StreetInsider
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth
March 16, 2026 8:01 AM - Globe NewsWire
Full Article List
